FFA
BMRN icon

Freedman Financial Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Freedman Financial Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-381
Closed -$31K – 50
2022
Q1 		$31K Hold
381
– – 0.02% 253
2021
Q4 		$34K Hold
381
– – 0.02% 248
2021
Q3 		$29K Hold
381
– – 0.02% 258
2021
Q2 		$32K Hold
381
– – 0.02% 245
2021
Q1 		$29K Hold
381
– – 0.02% 261
2020
Q4 		$33K Buy
+381
New +$30.2K 0.03% 235

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Freedman Financial Associates's BMRN Position: Q2 2022 in Review

Freedman Financial Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 381 shares — an estimated $31K sold.

Freedman Financial Associates first reported a position in BMRN in Q4 2020 and held it in 6 quarters. The position peaked at $34K in Q4 2021. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

  • Freedman Financial Associates reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 381 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $31K.
  • Freedman Financial Associates first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's BioMarin Pharmaceuticals position peaked at $34K in Q4 2021.
  • 542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.